ProPhase Labs (PRPH) Competitors $0.31 -0.01 (-4.26%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$0.33 +0.02 (+6.34%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. ANL, UNCY, TELO, VRCA, HOWL, ATNM, ZIVO, LTRN, DTIL, and KLRSShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Adlai Nortye (ANL), Unicycive Therapeutics (UNCY), Telomir Pharmaceuticals (TELO), Verrica Pharmaceuticals (VRCA), Werewolf Therapeutics (HOWL), Actinium Pharmaceuticals (ATNM), ZIVO Bioscience (ZIVO), Lantern Pharma (LTRN), Precision BioSciences (DTIL), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors Adlai Nortye Unicycive Therapeutics Telomir Pharmaceuticals Verrica Pharmaceuticals Werewolf Therapeutics Actinium Pharmaceuticals ZIVO Bioscience Lantern Pharma Precision BioSciences Kalaris Therapeutics Adlai Nortye (NASDAQ:ANL) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation. Do insiders and institutionals have more ownership in ANL or PRPH? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer ANL or PRPH? In the previous week, ProPhase Labs had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.00 beat ProPhase Labs' score of -0.67 indicating that Adlai Nortye is being referred to more favorably in the media. Company Overall Sentiment Adlai Nortye Neutral ProPhase Labs Negative Do analysts recommend ANL or PRPH? Adlai Nortye currently has a consensus price target of $9.00, indicating a potential upside of 471.43%. Given Adlai Nortye's stronger consensus rating and higher probable upside, research analysts clearly believe Adlai Nortye is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation and earnings, ANL or PRPH? Adlai Nortye has higher earnings, but lower revenue than ProPhase Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M11.62-$51.87MN/AN/AProPhase Labs$6.77M1.92-$53.36M-$1.26-0.25 Which has more risk & volatility, ANL or PRPH? Adlai Nortye has a beta of -0.95, suggesting that its share price is 195% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500. Is ANL or PRPH more profitable? Adlai Nortye's return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A ProPhase Labs N/A -184.38%-64.59% SummaryAdlai Nortye beats ProPhase Labs on 8 of the 12 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.97M$2.42B$5.51B$9.72BDividend YieldN/A1.78%4.60%4.12%P/E Ratio-0.2520.5930.0124.75Price / Sales1.92696.57450.7297.72Price / CashN/A172.9536.7758.47Price / Book1.254.328.185.59Net Income-$53.36M$31.61M$3.26B$265.99M7 Day Performance-4.26%0.01%6.13%5.07%1 Month Performance-27.36%-1.53%0.07%0.61%1 Year Performance-87.66%5.85%36.31%22.83% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs0.7303 of 5 stars$0.31-4.3%N/A-87.7%$12.97M$6.77M-0.25130Upcoming EarningsGap UpANLAdlai Nortye1.7263 of 5 stars$1.50+3.4%$9.00+500.0%-52.1%$53.51M$5M0.00127UNCYUnicycive Therapeutics2.6736 of 5 stars$4.19-0.2%$60.00+1,332.0%+15.2%$53.09MN/A-0.829Positive NewsTELOTelomir Pharmaceuticals3.2042 of 5 stars$1.83+4.0%$15.00+719.7%-63.6%$52.38MN/A-4.361News CoverageUpcoming EarningsGap DownVRCAVerrica Pharmaceuticals4.2088 of 5 stars$5.57-1.2%$80.00+1,336.3%-87.2%$52.17M$7.57M-0.4640Upcoming EarningsHOWLWerewolf Therapeutics3.5352 of 5 stars$1.24+6.9%$8.33+572.0%-38.1%$52.05M$1.88M-0.7440News CoverageUpcoming EarningsATNMActinium Pharmaceuticals2.0544 of 5 stars$1.66+3.1%$4.00+141.0%-24.5%$51.79MN/A-1.1930ZIVOZIVO BioscienceN/A$13.50+35.4%N/A+61.0%$51.53M$15.85K-2.7710Upcoming EarningsHigh Trading VolumeLTRNLantern Pharma2.2843 of 5 stars$5.32+11.5%$25.00+369.9%+27.8%$51.44MN/A-2.8920News CoverageShort Interest ↑Gap UpDTILPrecision BioSciences4.2427 of 5 stars$4.84+4.8%$47.00+871.1%-49.0%$51.23M$68.70M-2.41200News CoverageEarnings ReportKLRSKalaris TherapeuticsN/A$2.58-4.1%$3.00+16.3%N/A$50.31MN/A0.00110Gap Down Related Companies and Tools Related Companies ANL Competitors UNCY Competitors TELO Competitors VRCA Competitors HOWL Competitors ATNM Competitors ZIVO Competitors LTRN Competitors DTIL Competitors KLRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
